Family History-Based Colorectal Cancer Screening: Samir Gupta, MD

Colorectal cancer rates in younger adults are currently rising, and those with a family history of the disease face an even greater risk. Samir Gupta, MD, Chief of the Gastrointestinal (GI) Section of the San Diego Veterans Affairs Healthcare System, recently spoke with i3 Health about his research team's finding, now published in Cancer, that only 25% of patients between the ages of 40 to 49 who were diagnosed with colorectal cancer as a result of screening met the family history-based early sc...
Continue reading

Encorafenib/Cetuximab for BRAF V600E–Mutant Metastatic Colorectal Cancer: Scott Kopetz, MD, PhD, FACP

After patients with metastatic colorectal cancer who have a BRAF V600E mutation stop responding to first-line treatment, they have a median survival of only four to six months. These patients now have a new option in a combination therapy consisting of encorafenib (Braftovi®, Array BioPharma) and cetuximab (Erbitux®, Lilly), which was approved by the FDA earlier this month for adults with previously treated BRAF V600E-mutated metastatic colorectal cancer. In this interview with i3 Health, Scott ...
Continue reading

Family History-Based Screening Improves Colorectal Cancer Detection

In individuals with a family history of colorectal cancer, early screening improves detection, leading to a better prognosis in younger patients with this condition.Colorectal cancer rates in adults under the age of 50 are currently on the rise, and individuals with a family history of the disease face an even higher risk than the general population. Several societies, including the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiolo...
Continue reading

Encorafenib/Cetuximab Approved: Metastatic Colorectal Cancer With BRAF V600E Mutations

​The FDA has now approved encorafenib (Braftovi®, Array BioPharma) in combination with cetuximab (Erbitux®, Lilly) for adults with previously treated metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test."Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy," write Scott Kopetz, MD, PhD, FACP, and colleagues in their publicat...
Continue reading

Metastatic Colorectal Cancer: Treatment Challenges, Progress, and Advice With Chiara Cremolini, MD

Colorectal cancer is the third leading cause of cancer death and the fourth most common diagnosed cancer in the world. Often, this disease is left undiagnosed until it reaches an advanced stage. Unfortunately, late-stage metastatic colorectal cancer has a poor prognosis with a 5-year survival rate of only 12%. In an interview with i3 Health, Chiara Cremolini, MD, provides insights on the challenges of treating patients with metastatic colorectal cancer, explains how metastatic colorectal cancer ...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.